Company intelligence / Profile preview

Rendu Biotechnology

Shanghai, Shanghai, Chinardbio.com ↗

Ownership: Private
Development stage: Commercial

Overview

Rendu Biotechnology is a leading Chinese innovator in RNA molecular diagnostic technology, with commercialized products for reproductive health, respiratory diseases, bloodborne infections, and tumor early screening. Its SAT platform enables high-sensitivity detection of pathogens. The company’s COVID-19 test kit received emergency approval during the pandemic and its hepatitis B virus RNA kit was the world’s first such product approved for clinical use.

Therapeutic areas: Infectious Diseases
Modalities: RNA-based molecular diagnosticsDiagnostic reagents and devices (not therapeutics)
Industry: Molecular Diagnostics

Partnerships

Qiming Venture Partners is a key investor

Beyond the preview

Go deeper on Rendu Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rendu Biotechnology.

Explore the full profile